MENA 2024 Recordings-Anti estrogen and metabolic effects final 2

Video Transcription

Video Summary

The speaker at the RICH AACE conference discusses the metabolic effects of anti-estrogen therapy in breast cancer treatment. Breast cancer is the second most common cancer and leading cause of mortality in women globally. Anti-estrogen therapies, including selective estrogen receptor modulators (SERMs) like tamoxifen, aromatase inhibitors, and selective estrogen receptor degraders (SERDs), are used for treatment. These therapies, however, have significant side effects due to estrogen's role in various bodily functions outside the reproductive system, such as metabolism and bone health. Risks include diabetes, dyslipidemia, and fatty liver disease, primarily due to disrupted fat storage and altered lipid metabolism. Lifestyle interventions are crucial for managing these side effects. Emerging drug therapies like metformin and GLP-1 agonists show promise in reducing metabolic risks. Regular screening and healthy lifestyle habits are essential for women undergoing anti-estrogen therapy.

Keywords

breast cancer

anti-estrogen therapy

metabolic effects

selective estrogen receptor modulators

lifestyle interventions

metformin